### Award Mechanism

<table>
<thead>
<tr>
<th>Idea Development Award</th>
<th>For Single Principal Investigator (PI) applications:</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Go to:</td>
<td>Investigators at or above the level of Assistant Professor (or equivalent) or For Partnering PI Option for Early-Career Investigator: The Initiating PI (mentor) must be at or above the level of Assistant Professor (or equivalent) to be named by the organization as the PI on the application. By the full application submission date, the Partnering PI (Early-Career Investigator) must:  - Have instructor-level (or equivalent) faculty appointment or above.  - Be no more than 10 years from the receipt of a terminal degree (excluding time spent in residency or on family medical leave) at the time of the application deadline.</td>
<td>- Supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with pancreatic cancer.  - Research must address at least one of the FY24 PCARP Focus Areas.  - This award cannot be used to conduct clinical trials or proof-of-concept intervention studies on human subjects.  - For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research.  - Pre-application submission is required; application submission is by invitation only.</td>
<td><strong>Established Single PI Option:</strong>  - The maximum allowable funding for the entire period of performance is $500,000 for direct costs.  - Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  - The maximum period of performance is 3 years. <strong>Early-Career Investigator Partnering PI Option:</strong>  - The maximum allowable funding for the entire period of performance is $650,000 for direct costs.  - Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  - The maximum period of performance is 3 years.</td>
<td><strong>Pre-Application (Preproposal):</strong>  June 28, 2024 5:00 p.m. Eastern time  <strong>Application:</strong>  October 3, 2024 11:59 p.m. Eastern time</td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadline</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------</td>
</tr>
</tbody>
</table>
| Translational Research Partnership Award | **Principal Investigator (PI):** The Translational Research Partnership Award requires two PIs. One partner in the collaboration must function as a research scientist and the other as a clinician investigator (Initiating and Partnering PI)  
- PIs must be at or above the level of Assistant Professor or equivalent.  
- Clinician investigators must be an M.D., M.D./Ph.D., or equivalent with clinical duties.  
- Postdoctoral and clinical fellows are not eligible.  
- At least one member of the partnership must have expertise either in pancreatic cancer research or pancreatic cancer patient care. | Projects involving convergence science partnerships are strongly encouraged.  
- Supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts  
- Research must address at least one of the FY24 PCARP Focus Areas.  
- Preliminary data to support the feasibility of the research hypothesis(es) and research approaches are required; however, these data do not necessarily need to be derived from studies of pancreatic cancer. | The maximum allowable funding for the entire period of performance for the Initiating and Partnering PIs’ applications will not exceed $750,000 in direct costs.  
- The PIs are expected to be partners in the research, and direct cost funding should be divided accordingly.  
- If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate.  
- The maximum period of performance is 3 years. | Pre-Application (Preproposal): June 28, 2024 5:00 p.m. Eastern time  
Application: October 3, 2024 11:59 p.m. Eastern time |
| Focused Pilot Award                    | **Principal Investigator (PI):** Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the PI on the application.  
There are no limitations on the number of applications for which an investigator may be named as a PI.  
An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization. | Letter of Intent (LOI) submission is required; an invitation to submit is not required.  
- Supports the exploration and development of impactful and innovative concepts under two patient-centered focus areas of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life.  
- Research supported by this award should strive to produce robust preliminary data that can be used as a foundation for future clinical or real-world research application  
- Research must address at least one of the FY24 PCARP Focused Pilot Award Focus Areas:  
  - Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship.  
  - Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities. | The maximum allowable funding for the entire period of performance is $200,000 for direct costs.  
- Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
- The maximum period of performance is 2 years. | Pre-Application (Preproposal): September 18, 2024 5:00 p.m. Eastern time  
Application: October 3, 2024 11:59 p.m. Eastern time |